Form 4: Lyra Therapeutics CEO Earns Performance Stock Options

Lyra Therapeutics' President & CEO, Maria Palasis, earned 3,667 performance stock options after achieving a key milestone.

Summary

• Maria Palasis, President & CEO and Director of Lyra Therapeutics, Inc. (LYRA), reported the acquisition of performance stock options (PSOs).
• On October 1, 2025, Milestone 2 of a previously granted PSO was achieved, resulting in 3,667 PSOs being earned.
• The original PSO, granted on March 21, 2024, was for an aggregate of up to 11,000 shares of common stock (or 550,000 shares on a pre-split basis) under the Issuer's 2020 Incentive Award Plan.
• The earned PSOs have an exercise price of $303.5 per share and will vest on January 31, 2028.
• The options have an expiration date of March 20, 2034.
• Following this transaction, Maria Palasis beneficially owns 7,333 derivative securities.

Sentiment

Score: 8

Explanation: The filing indicates a positive event where an executive achieved a performance milestone, leading to the earning of stock options. This suggests progress and aligns management incentives with shareholder value.

Positives

• The achievement of a performance milestone indicates progress in the company's strategic objectives.
• The earning of performance stock options aligns management's interests with those of shareholders, incentivizing long-term value creation.
• The active vesting of incentive awards demonstrates the company's commitment to its compensation plan and rewarding executive performance.

Future Outlook

The earned performance stock options are scheduled to vest on January 31, 2028, indicating a future milestone for the executive's compensation.

Industry Context

This filing details an executive compensation event, specifically the earning of performance-based stock options, which is a common practice across various industries to incentivize executive performance and align interests with shareholders. It does not directly relate to broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: Positive impact as the achievement of a performance milestone by the CEO suggests progress and aligns executive incentives with shareholder value.
• Employees: Positive impact as it demonstrates the company's incentive plan is active and rewards performance, potentially boosting morale and motivation.

Next Steps

• The earned performance stock options will vest on January 31, 2028.

Key Dates

Keywords

Lyra Therapeutics, LYRA, Performance Stock Option, Executive Compensation, Insider Transaction, SEC Form 4, Stock Option Grant, Milestone Achievement